Health Care • Biotechnology: Commercial Physical & Biological Resarch
$652.01 ▼ -25.55
(-3.77%)
MKT CAP: $18.95B • VOL: 219.6K
52W L $373 52W H $694
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$548
MEDIAN
$730
MEAN
$743
HIGH
$887
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MEDP TAPE
MEDP // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $788.93 | $749.81 | 2025-02-14 | $593.33 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $821.53 | $769.37 | 2025-02-06 | $612.89 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $743.29 | $717.21 | 2025-01-29 | $625.93 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $665.05 | — | 2025-01-17 | $638.97 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $573.77 | $619.41 | 2025-01-09 | $580.29 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $775.89 | $678.09 | 2024-12-18 | $567.25 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $632.45 | $658.53 | 2024-12-04 | $606.37 | -4.3% | 48% | C |